Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 16 June 2025 AM
Eli Lilly has dropped plans to list Ebglyss on the PBS and called for urgent HTA reform after struggling to secure a commercially viable price for the eczema drug, which will remain available on private script.
For the company, it’s a case of deja vu, which halted the launch of its highly anticipated ulcerative colitis treatment Omvoh in January 2024 due to pricing issues.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.